Icosavax Insiders Forfeit On 41% Gains After Selling Stock
Icosavax Insiders Forfeit On 41% Gains After Selling Stock
While Icosavax, Inc. (NASDAQ:ICVX) shareholders have had a good week with the stock up 41%, insiders can't say the same having sold stock over the past year. The value of their investment would have been higher had they waited to sell their stock.
雖然Icosavax,Inc. (NASDAQ:ICVX)的股東本週股價上漲了41%,但內部人士在過去一年中賣出了股票,他們的投資價值如果等待賣出股票則會更高。
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
雖然在長期投資方面內部交易並非最重要的事情,但完全忽略內部交易是愚蠢的。
See our latest analysis for Icosavax
請查看我們對Icosavax的最新分析
Icosavax Insider Transactions Over The Last Year
過去一年,我們可以看到最大的內部人士銷售是由內部人士Douglas Holtzman進行的,價值21.9萬美元的股票,每股約11.14美元。我們通常不喜歡看到內部人士賣出股票,但售價越低,我們就越擔心。好消息是,這次減持是在最新價格(9.30美元)之上進行的。因此,這可能對內部人士對當前股價的看法並無影響。Douglas Holtzman是過去一年中唯一一個賣出股票的個人內部人士。
Over the last year, we can see that the biggest insider sale was by the insider, Douglas Holtzman, for US$219k worth of shares, at about US$11.14 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$9.30). So it may not tell us anything about how insiders feel about the current share price. Douglas Holtzman was the only individual insider to sell over the last year.
過去一年中,我們可以看到最大的內部人士銷售是由內部人士Douglas Holtzman進行的,價值21.9萬美元的股票,每股約11.14美元。我們通常不喜歡看到內部人士賣出股票,但售價越低,我們就越擔心。好消息是,這次減持是在最新價格(9.30美元)之上進行的。因此,這可能對內部人士對當前股價的看法並無影響。Douglas Holtzman是過去一年中唯一一個賣出股票的個人內部人士。
The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
下面的圖表顯示了過去一年內公司和個人的內部交易情況。如果您想確切地知道誰以多少價錢在何時賣出,請單擊下面的圖表!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找獲勝投資的人,這個具有最近內部購買的增長型公司免費列表可能是您的不二選擇。
Insider Ownership Of Icosavax
Icosavax的內部持股
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 3.4% of Icosavax shares, worth about US$16m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
查看公司的總內部股份持有量可以幫助了解他們是否與普通股東利益一致。較高的內部持股通常會使公司領導更加關注股東利益。內部人士持有Icosavax股份的比例爲3.4%,價值約1600萬美元。雖然這是一個強勢但並不是傑出的內部持股水平,但足以表明管理層與較小的股東之間存在一定的利益一致性。
What Might The Insider Transactions At Icosavax Tell Us?
Icosavax的內部交易可能會告訴我們什麼?
There haven't been any insider transactions in the last three months -- that doesn't mean much. Still, the insider transactions at Icosavax in the last 12 months are not very heartening. But it's good to see that insiders own shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Icosavax. When we did our research, we found 4 warning signs for Icosavax (1 is concerning!) that we believe deserve your full attention.
過去三個月內沒有內部交易,這並不意味着很多。然而,Icosavax在過去12個月的內部交易情況並不令人鼓舞。但很高興看到內部者擁有公司股份。除了了解正在進行的內部交易,識別Icosavax面臨的風險也是有益的。在我們的研究中,我們發現Icosavax存在4個警示信號(其中1個令人擔憂!)我們認爲值得您充分關注。
Of course Icosavax may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,Icosavax可能不是最好的股票可買入。因此,您可能希望查看這些優質公司的免費收藏。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。